Your session is about to expire
← Back to Search
Allograft Tissue
Nucel treatment group for Degenerative Disc Disease
N/A
Waitlist Available
Led By Pierce Nunley, MD
Research Sponsored by Organogenesis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
This trial looks at whether a certain allograft tissue is safe and effective to use in lumbar interbody fusion procedures.
Eligible Conditions
- Degenerative Disc Disease
- Spondylolisthesis
- Spondylosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Fusion rate using non-contrast CT of the lumbar spine
Other outcome measures
Neurologic Exam
Oswestry Low Back Pain Disability Index
SF-12 health survey
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Nucel treatment groupExperimental Treatment2 Interventions
One or two level lumbar interbody fusion surgery with Nucel
Find a Location
Who is running the clinical trial?
OrganogenesisLead Sponsor
35 Previous Clinical Trials
4,070 Total Patients Enrolled
Pierce Nunley, MDPrincipal InvestigatorSpine Institute of Louisiana
1 Previous Clinical Trials
135 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger